TICK-BORNE ENCEPHALITIS (TBE) VACCINE

Katherine Poehling, MD, MPH
Chair, ACIP TBE Vaccine Work Group
January 12, 2022
Background

- Food and Drug Administration approved a TBE vaccine (manufactured by Pfizer as TICOVAC) in August 2021
- No TBE vaccine previously licensed in the United States
- No existing ACIP TBE vaccine recommendations
- TBE Vaccine Work Group formed in September 2020 to review use of TBE vaccine in US persons traveling abroad and laboratory workers
<table>
<thead>
<tr>
<th>ACIP</th>
<th>ACIP liaisons</th>
<th>Technical advisors (cont’d)</th>
<th>CDC participants (cont’d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katherine Poehling (Chair)</td>
<td>David Shlim, ISTM</td>
<td>Steven Schofield, CATMAT</td>
<td>Stacey Martin, DVBD</td>
</tr>
<tr>
<td>Wilbur Chen</td>
<td>Mark Sawyer, AAP</td>
<td>Bryan Schumacher, DOD</td>
<td>Michael McNeil, DHQP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mary Wilson, Univ Calif SFO</td>
<td>Rebecca Morgan, Consultant</td>
</tr>
<tr>
<td>CDC Lead</td>
<td>Technical advisors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan Hills, DVBD</td>
<td>Alan Barrett, Univ Texas Galveston</td>
<td>CDC participants</td>
<td>Steve Waterman, DVBD</td>
</tr>
<tr>
<td></td>
<td>Lin Chen, Mount Auburn Hosp</td>
<td>Grace Appiah, DGMQ</td>
<td></td>
</tr>
<tr>
<td>Ex Officio</td>
<td>Tony Marfin, PATH</td>
<td>Doug Campos-Outcalt, Consultant</td>
<td>ACIP Secretariat</td>
</tr>
<tr>
<td>Rodolfo (Rudy) Alarcon, NIH</td>
<td>Bruce McClanathan, DOD</td>
<td>Susan Chu, GID</td>
<td>Jessica MacNeil, NCIRD</td>
</tr>
<tr>
<td>Ihid Carneiro Leao, FDA</td>
<td>Kayvon Modjarrad, DOD</td>
<td>Caitlin Cossaboom, DHCPP</td>
<td>Melinda Wharton, NCIRD</td>
</tr>
</tbody>
</table>
Terms of Reference for TBE Vaccine Work Group

- To review information on TBE, including its epidemiology, clinical presentation, diagnosis, treatment, and outcome
- To review data on infection risk and burden for travelers and laboratory workers
- To review data on vaccine safety, immunogenicity, and effectiveness
- To provide evidence-based recommendation options for ACIP
- To identify areas in need of further research for informing potential future vaccine recommendations
- To publish ACIP recommendations in the Morbidity and Mortality Weekly Report (MMWR)
Overview of previous Work Group presentations to ACIP

- **October 2020**
  - Background on TBE disease and vaccines
  - Summary information on Pfizer’s TBE vaccine

- **February 2021**
  - TBE epidemiology in TBE endemic areas
  - TBE among US civilian travelers and laboratory workers
  - TBE among US military personnel

- **September 2021**
  - Immunogenicity and safety of Pfizer’s TBE vaccine
Overview of today’s session

- Follow up of ACIP member questions
  - Immunogenicity of 1 or 2 doses of TBE vaccine

- Evidence to Recommendations for TBE vaccine
  - Persons who travel abroad
  - Laboratory workers

- Next steps
Work Group timeline (planned), Jan–Mar 2022

Aug → Sep → Oct → Nov → Dec → Jan → Feb → Mar

- Present to ACIP (today): Evidence to Recommendations
- ACIP vote on vaccine recommendations and finalize MMWR